Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
"CLCZ696B2401-TRANSITION (A multicenter, randomized, open label, parallel group studycomparing pre-discharge and posT-discharge tReatmentinitiation with LCZ696 in heArt failure patieNtS withreduced ejectIon-fracTion hospItalized for an acutedecOmpensation eveNt (ADHF)"	Novartis	Ongoing	Entresto (SACUBITRIL, VALSARTAN)	4	CZ696B2401	Saud Al-Babtain Cardiac Center (Dammam), King Faisal Specialist Hospital and Research Center (Jeddah), King Faisal Specialist Hospital and Research Center (Riyadh), King Khalid University Hospital (Riyadh)
"A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition tothe Paliperidone Palmitate 3-Month Formulation in Patients with SchizophreniaPreviously Stabilized on the Paliperidone Palmitate 1-Month Formulation"	Janssen-Cilag International NV	Ongoing	paliperidone	3	R092670SCH3015	Jeddah psychiatric hospital, Al-Amal Complex for mental health (Dammam)
"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial withan open-label extension that investigates the effect of the addition of dulaglutide (0.75 and1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baselinein hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus"	Eli Lilly	Ongoing	Dulaglutide 0.75 /1.5 mg	3	H9X-MC-GBGC	King Khalid University Hospital (Riyadh), International Medical Center (Jeddah)
"A Randomized controlled Trial of Influenza Vaccineto Reduce Adverse Vascular Events"	McMaster University	Ongoing	Vaxigrip	3	version 2	King Khalid University Hospital (Riyadh), King Abdulaziz University Hospital (Jeddah), King Fahad Medical City (Riyadh), Madinah Cardiac Center
RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity	Novartis	Ongoing	Ranibizumab	3	CRFB002H2301 V 01	King Faisal Specialist Hospital and Research Center (Riyadh)
RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity	Novartis	Ongoing	Ranibizumab	3	CRFB002H2301 V 01	King Faisal Specialist Hospital and Research Center (Riyadh)
Phase 2 study of 5 Days azacytidine priming prior to fludarabine, cytarabine and G-CSF combination for patients with relapsed or refractory AML.	King Fahad Medical City	Ongoing	Vidaza	2	Version 1.1	King Fahad Medical City (Riyadh)
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	Bristol-Myers Squibb	Terminated	NIVOLUMAB/IPILIMUMAb	3	CA209-227	King Faisal Specialist Hospital and Research Center (Riyadh)
Asia and Latin America Fracture Observational Study	Eli Lilly	Ongoing	Forteo (teriparatide)	4	B3D-MC-B02	King Fahad Medical City (Riyadh), Al-Noor Specialist Hospital, King Fahad Hospital (Jeddah), Sabia General Hospital, King Saud Medical City (Riyadh), King Fahad University Hospital (Al-Khobar)
"A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety ofAbatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults with Early Rheumatoid Arthritis who are Methotrexate Naive"	Bristol-Myers Squibb	Terminated	Abatacept	3b	IM101550	King Fahad Medical City (Riyadh)